ARUP's Laboratory Test Directory
| 0059444: Purkinje Cell Cytoplasmic Antibody by IFA with Reflex to Titer & Immunoblot |
| Test Mnemonic: PCCA R | |
|
Methodology: Indirect Fluorescent Antibody/Immunoblot
Performed: Wed Reported: 1-9 days |
| Specimen Required: | |
|
Collect: One 4 mL SST.
Transport: 1 mL serum, frozen. (Min: 0.5 mL) Submit specimen in an ARUP Standard Transport Tube. Pediatric Collection/Transport: 0.5 mL serum, frozen. Remarks: Separate serum from cells ASAP. Unacceptable Conditions: Plasma. Lipemic, hemolyzed, contaminated or heat-inactivated specimens. Stability: After separation from cells: Ambient: 2 days; Refrigerated: 2 weeks; Frozen: 1 year |
|
| Reference Interval: | ||||||||
|
| Interpretive Data: | |
|
There is a strong association among paraneoplastic syndromes, anti-neuronal antibody specifications and the associated tumor type. However, in a minority of patients with paraneoplastic syndrome with anti-neuronal antibodies, no tumor may be found. Certain patients with paraneoplastic syndromes may not have detectable levels (by IFA) of anti-neuronal antibodies. Most cases that develop PCD in association with Hodgkin's disease, non-SCLC, gastrointestinal carcinomas do not have demonstrable anti-Yo antibodies. There also exist anti-Yo negative but atypical anti-Purkinje cell cytoplasm autoantibodies (atypical APCA's). Such antibodies can occur in association with Hodgkin's disease, adenocarcinoma of the lung, colon, or prostate. 5-6% patients with ovarian cancer have circulating anti-Yo or anti-Ri antibodies in the absence of any paraneoplastic neurological syndromes.
Please refer to Statement D in the Compliance Statements section in the front of the Laboratory Test Directory. |
| Note: | |
| If Purkinje cell screen is 1:10, then a titer and immunoblot will be added. |
| CPT Code(s): | |
| 86255; if reflexed, add 86256 Titer; 83516 Immunoblot |